Lymphohaematopoietic Growth Factors in Cancer Therapy

Recent experimental and clinical progress in the evaluation of cytokines in treatment concepts for cancer patients is the central theme of this book in the ESO Monographs series. The discussion revolves on the experimental basis as well as current clinical experience with the use of human recombinant cytokines. It gives the state of the art and, as such, puts into perspective potential areas of growth and future research.

The newest volume in the series sponsored by the European School of Oncology, it reports on the state of the art as surveyed in an ESO task force.

Contents: Introduction.- Interleukins and Haematopoietic Growth Factors.- Mechanisms of T-Cell Activation.- Characteristics of LAK Cells and Their Use in Adoptive Therapy of Cancer in Experimental Animals.- Interleukin 2: In Vivo Induction of Effector Cells.- Cellular Immunotherapy of Cancer: The Use of Lymphokine-Activated Natural Killer (LANAK) Cells.- Interleukin 2: Clinical Aspects.- Interleukin 2 and LAK Cells.